<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36969217</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study.</ArticleTitle><Pagination><StartPage>1062919</StartPage><MedlinePgn>1062919</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1062919</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1062919</ELocationID><Abstract><AbstractText Label="OBJECTIVES">IGU (IGU), a novel immunomodulatory agent for rheumatoid arthritis, has been shown to be effective and safe as monotherapy in a small population with refractory lupus nephritis (LN). The aim of this prospective study was to evaluate the efficacy and safety of IGU as an add-on therapy in patients with refractory LN in the context of clinical practice.</AbstractText><AbstractText Label="METHODS">This is a single-arm observational study. We have enrolled LN patients since 2019 at Renji Hospital. All participants should have recurrent or refractory LN with at least one immunosuppressant (IS) and have a baseline urine protein/creatinine ratio (UPCR) &gt;1.0. After enrollment, we added IGU (25 mg twice daily) to one of their previous immunosuppressants (IS) without increasing the dose of steroids. The primary outcome was the complete renal response (CRR) in the 6th month. UPCR decrease of over 50% was defined as partial response (PR). Extended follow-up was performed after the initial 6 months.</AbstractText><AbstractText Label="RESULTS">We enrolled 26 eligible participants. 11/26 patients had chronic kidney disease (CKD) stage 2/3 at the baseline. The IS combined with IGU included mycophenolate mofetil, tacrolimus, and cyclosporin A. No IS change was allowed. 80.7% of patients had baseline steroids less than 0.5mg/kg daily and there was no steroids escalation during the IGU treatment. The CRR rate was 42.3% (11/26) at month 6. With a median follow-up of 52 weeks (range: 23-116 weeks), the CRR rate at the last visit was 50% (13/26) and 73.1% (19/26) of patients had UPCR decrease of over 50%. Six patients withdrew, three for no response and three for renal flare after initial CRR. One patient had an estimated glomerular filtration rate worsening of over 20% and was classified as renal flare. Three mild to moderate adverse events were recorded.</AbstractText><AbstractText Label="CONCLUSIONS">Our investigation merits further investigation in IGU as a potentially tolerable component of combination therapy for refractory LN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Yan, Zhang, Du, Kang, Ye, Li, Liu, Dai and Bao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Qingran</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Anhui Public Health Clinical Center, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Yuening</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Chunde</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4IHY34Y2NV</RegistryNumber><NameOfSubstance UI="C519076">iguratimod</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IGU</Keyword><Keyword MajorTopicYN="N">add-on</Keyword><Keyword MajorTopicYN="N">combinational therapy</Keyword><Keyword MajorTopicYN="N">prospective study</Keyword><Keyword MajorTopicYN="N">refractory lupus nephritis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36969217</ArticleId><ArticleId IdType="pmc">PMC10030952</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1062919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol (2012) 2012:1&#x2013;9. doi:&#xa0;10.1155/2012/604892</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/604892</ArticleId><ArticleId IdType="pmc">PMC3368358</ArticleId><ArticleId IdType="pubmed">22690240</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Brunner HI. Pediatric lupus&#x2013;are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheumatic Dis Clinics North America (2010) 36(1):53&#x2013;80. doi:&#xa0;10.1016/j.rdc.2009.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2009.12.012</ArticleId><ArticleId IdType="pmc">PMC2837537</ArticleId><ArticleId IdType="pubmed">20202591</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol (2017) 12(5):825&#x2013;35. doi:&#xa0;10.2215/CJN.05780616</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05780616</ArticleId><ArticleId IdType="pmc">PMC5477208</ArticleId><ArticleId IdType="pubmed">27821390</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. . 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis (2019) 78(6):736&#x2013;45. doi:&#xa0;10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS. Multiethnic lupus cohorts: What have they taught us? Reumatolog&#xed;a Cl&#xed;nica (2011) 7(1):3&#x2013;6. doi:&#xa0;10.1016/j.reuma.2010.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2010.11.001</ArticleId><ArticleId IdType="pubmed">21794772</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheumatol (2007) 56(4):1263&#x2013;72. doi: 10.1002/art.22505</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22505</ArticleId><ArticleId IdType="pubmed">17393458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lateef A, Lahiri M, Teng GG, Vasoo S. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus (2010) 19(6):765&#x2013;70. doi: 10.1177/0961203309358599</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309358599</ArticleId><ArticleId IdType="pubmed">20118162</ArticleId></ArticleIdList></Reference><Reference><Citation>Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant (2010) 25(11):3586&#x2013;92. doi: 10.1093/ndt/gfq256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfq256</ArticleId><ArticleId IdType="pubmed">20466686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. . 2019 Update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis (2020) 79(6):713&#x2013;23. doi: 10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus (2018) 27(6):1007&#x2013;11. doi: 10.1177/0961203318758505</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318758505</ArticleId><ArticleId IdType="pubmed">29448881</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. . Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med (2015) 162(1):18&#x2013;26. doi: 10.7326/M14-1030</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-1030</ArticleId><ArticleId IdType="pubmed">25383558</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus D, Rodrigues M, da Silva JAP, Ines L. Multitarget therapy of mycophenolate mofetil and cyclosporine a for induction treatment of refractory lupus nephritis. Lupus (2018) 27(8):1358&#x2013;62. doi: 10.1177/0961203318758508</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318758508</ArticleId><ArticleId IdType="pubmed">29448882</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med (2020) 383(12):1117&#x2013;28. doi: 10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. . Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (2021) 397(10289):2070&#x2013;80. doi: 10.1016/S0140-6736(21)00578-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. . B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2022) 81(1):100&#x2013;7. doi: 10.1136/annrheumdis-2021-220920</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. . Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis (2022) 81(4):496&#x2013;506. doi: 10.1136/annrheumdis-2021-221478</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K. Iguratimod (T-614): A novel disease modifying anti-rheumatic drug. Rheumatol Rep (2009) 1(1):e4. doi: 10.4081/rr.2009.e4</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/rr.2009.e4</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. . Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Modern rheumatology/the Japan Rheumatism Assoc (2007) 17(1):1&#x2013;9. doi: 10.3109/s10165-006-0542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/s10165-006-0542-y</ArticleId><ArticleId IdType="pubmed">17278015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, et al. . Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J (2008) 121(7):615&#x2013;9. doi: 10.1097/00029330-200804010-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00029330-200804010-00008</ArticleId><ArticleId IdType="pubmed">18466681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. . Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheumatol (2009) 61(7):979&#x2013;87. doi: 10.1002/art.24643</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24643</ArticleId><ArticleId IdType="pubmed">19565542</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflammation Res (2002) 51(4):188&#x2013;94. doi: 10.1007/PL00000291</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00000291</ArticleId><ArticleId IdType="pubmed">12058956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. . Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol (2001) 28(12):2591&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11764202</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, et al. . A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol (2013) 191(10):4969&#x2013;78. doi: 10.4049/jimmunol.1300832</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300832</ArticleId><ArticleId IdType="pubmed">24123677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, et al. . Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem (2016) 291(51):26502&#x2013;14. doi: 10.1074/jbc.M116.743328</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.743328</ArticleId><ArticleId IdType="pmc">PMC5159510</ArticleId><ArticleId IdType="pubmed">27793992</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol (1995) 67(4):305&#x2013;14. doi: 10.1254/jjp.67.305</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jjp.67.305</ArticleId><ArticleId IdType="pubmed">7650864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Du F, Huang X, Fu Q, Chen S, Dai D, et al. . Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PloS One (2014) 9(10):e108273. doi: 10.1371/journal.pone.0108273</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0108273</ArticleId><ArticleId IdType="pmc">PMC4182720</ArticleId><ArticleId IdType="pubmed">25271634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Liu M, Tang L, Du F, Liu Y, Hao P, et al. . Iguratimod represses b cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. Arthritis Res Ther (2019) 21(1):92. doi: 10.1186/s13075-019-1874-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1874-2</ArticleId><ArticleId IdType="pmc">PMC6458835</ArticleId><ArticleId IdType="pubmed">30971291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y, Yan Q, Fu Q, Wang R, Dai M, Du F, et al. . Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study. Arthritis Res Ther (2020) 22(1):65. doi: 10.1186/s13075-020-02154-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02154-7</ArticleId><ArticleId IdType="pmc">PMC7106733</ArticleId><ArticleId IdType="pubmed">32228698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. . Joint European league against rheumatism and European renal association&#x2013;European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheumatic Dis (2012) 71(11):1771&#x2013;82. doi: 10.1136/annrheumdis-2012-201940</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201940</ArticleId><ArticleId IdType="pmc">PMC3465859</ArticleId><ArticleId IdType="pubmed">22851469</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa Y, Tanuma N, Shin T, Makino S, Tanaka K, Matsumoto Y. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol (1998) 89(1-2):35&#x2013;42. doi: 10.1016/S0165-5728(98)00056-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(98)00056-3</ArticleId><ArticleId IdType="pubmed">9726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Liu B, Yang M, Li Q, Wang J, Li T, et al. . Duration biased distribution of clinical and immunological phenotypes in active SLE. Front Immunol (2022) 13:1044184. doi: 10.3389/fimmu.2022.1044184</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1044184</ArticleId><ArticleId IdType="pmc">PMC9794596</ArticleId><ArticleId IdType="pubmed">36591231</ArticleId></ArticleIdList></Reference><Reference><Citation>Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. (2009) 4(2):481&#x2013;508. doi: 10.2215/CJN.04800908</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04800908</ArticleId><ArticleId IdType="pubmed">19218475</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. (2009) 20(5):1103&#x2013;12. doi: 10.1681/ASN.2008101028</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008101028</ArticleId><ArticleId IdType="pmc">PMC2678035</ArticleId><ArticleId IdType="pubmed">19369404</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. . Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol (2021) 73(1):121&#x2013;31. doi: 10.1002/art.41466</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41466</ArticleId><ArticleId IdType="pmc">PMC7839443</ArticleId><ArticleId IdType="pubmed">32755035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, et al. . Long-term effects of combined b-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant (2021) 36(8):1474&#x2013;83. doi: 10.1093/ndt/gfaa117</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfaa117</ArticleId><ArticleId IdType="pmc">PMC8311580</ArticleId><ArticleId IdType="pubmed">32591783</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Yamasaki R, Fang M, Masaki K, Ochi H, Matsushita T, et al. . Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-&#x3ba;B pathway. Sci Rep (2018) 8(1):1933. doi: 10.1038/s41598-018-20390-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20390-5</ArticleId><ArticleId IdType="pmc">PMC5792543</ArticleId><ArticleId IdType="pubmed">29386552</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C, Chen S, Karp DR, Saxena R, Sambandam K, Chakravarty E, et al. . Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol (2017) 185:3&#x2013;9. doi: 10.1016/j.clim.2016.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.11.019</ArticleId><ArticleId IdType="pmc">PMC5457715</ArticleId><ArticleId IdType="pubmed">27923701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesar V, Hruskova Z. Lupus nephritis: A different disease in European patients? Kidney Dis (Basel) (2015) 1(2):110&#x2013;8. doi: 10.1159/000438844</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000438844</ArticleId><ArticleId IdType="pmc">PMC4934820</ArticleId><ArticleId IdType="pubmed">27536671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>